Skip to content

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Amgen logo
AmgenAMGN
$9.19B+48.1%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$391.51M+135%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$524M-1.3%
Erasca, Inc. logo
Erasca, Inc.ERAS
$393.53M-1.5%
Immunome logo
ImmunomeIMNM
$588.69M+91.7%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s total equity?
IDEAYA Biosciences, Inc. (IDYA) reported total equity of $937.27M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s total equity changed year-over-year?
IDEAYA Biosciences, Inc.'s total equity decreased by 8.5% year-over-year, from $1.02B to $937.27M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s total equity?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s total equity has grown at a 38.8% compound annual growth rate (CAGR), from $198.27M to $1.02B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.